Open in app

FDA Approved Molnupiravir for COVID-19 Treatment.

img-1
Total Views:
98
img-1
Total Likes:
10
img-1
Published By:
Peeyush Ghalot
img-1
Published On:
25-12-2021

US health officials approved a second tablet to treat COVID-19, delivering another easy-to-use treatment to combat the growing flood of Omicron infections. Due to its higher advantages and lesser side effects, Paxlovid is expected to become the first-choice therapy for the infection. Its effectiveness to prevent severe COVID-19 is less than expected, and the medicine label will warn of significant side effects, including the risk of birth abnormalities. The FDA has approved Merck's medication for persons with early COVID-19 symptoms at high risk of hospitalization, such as the elderly and those with comorbidities including obesity and heart disease.

(Picture: - Science News)

Molnupiravir is an orally given ribonucleoside analog that prevents SARS-CoV-2, which causes COVID-19, from replicating. After licensing the medicine from Emory University, Merck and Ridgeback Biotherapeutics work jointly to produce molnupiravir. Molnupiravir has previously been approved for use in the United Kingdom, and the United States has reordered over 3 million doses. Molnupiravir will be labelled with a warning that it should not be taken while pregnant.

Reference: - https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain